Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

Abstract Background Low-density lipoprotein (LDL-C) lowering is imperative in cardiovascular disease prevention. Effectively translating the evidence for LDL-C to maximize clinical and public health benefits depends on availability of accurate results from laboratories guide therapy. Furthermore, prior work has raised possibility that cholesterol esterase transfer protein (CETP) inhibition could interfere with assessment LDL-C. Purpose We aimed compare accuracy three clinically implemented equations a trial CETP inhibition. Methods Men women aged 18–75 years dyslipidaemia were recruited 17 sites Netherlands Denmark. Patients randomly assigned one nine groups using various combinations inhibitor TA-8995, statin therapy, placebo. In pooled measurements over 12 weeks, we calculated by Friedewald, Martin/Hopkins, Sampson equations, compared values preparative ultracentrifugation (PUC) as reference measure (also known “beta quantification”). Based literature guidelines, examined correct classifications across 1.81 mmol/L cutpoint subgroup patients triglycerides 1.69–4.51 mmol/L. Results The analysis included 242 contributing 921 observations. full distributions differences between estimates PUC are shown Figure 1. Overall median small: 0.00 (25th, 75th: −0.10, 0.08) mmol/L; 0.02 (−0.08, 0.10) Sampson, 0.05 (−0.03, 0.15) estimated <1.81 mmol/L, Friedewald equation underestimated difference versus −0.25 (−0.33, −0.10) whereas Martin/Hopkins corrected this issue showed tendency towards underestimation −0.06 (−0.13, 0.00) triglyceride levels 2 shows proportion classified < or ≥1.81 correctly when PUC. All >95% However, observations was 71.4% 100.0% 93.1% Sampson. Conclusion Europeans dyslipidaemia, our improved contemporary equation, particularly equation. High seen individuals treated even context low high levels. Funding Acknowledgement Type funding sources: Private company. Main source(s): Dezima NewAmsterdam Pharma